Early Access — free while we kick the tires
EdgarHawk

Francis Lo

Chief People Officer

Officer

Latest: Chief People Officer selling · June 2026

4 filings analyzed · 1 company · Latest 2026-06-08

Companies

Company Buys Sells Direction
Adaptive Biotechnologies Corp ADPT 0 15 Net selling

Activity

June 2026
Sell
39,741 shares
$695,070
Significance 4/10

CPO Francis Lo sells 39,741 ADPT shares at $17.49 under pre-arranged 10b5-1 plan; holds 250,934 shares post-sale plus 483,489 in stock options.

Francis Lo, Chief People Officer, executed a scheduled sale of 39,741 shares for $695,070.09 on 2026-06-04 under a pre-arranged 10b5-1 trading plan adopted on 2025-09-15, meaning this was a non-discretionary, predetermined transaction. Lo retains 250,934 non-derivative shares post-transaction alongside derivative holdings totaling 483,489 shares across four stock option vehicles, so his overall economic exposure to ADPT remains substantial. The company faces significant near-term headwinds: it posted a net loss of $-20,033,000.00 on quarterly revenue of $70,874,000.00 and remains unprofitable on a full-year basis, despite strong annual revenue growth of +54.8%. The stock is down 19.6% from its 52-week high of $20.76, though it has recovered 20.9% over the prior 30 days and 15.0% over 90 days.

March 2026
medium
Sell
38,074 shares
$574,537
Significance 5/10

Chief People Officer Francis sold 38,074 shares of ADPT at $15.09; stock -26.9% from 52-week high at $14.95

Francis sold 38,074 shares (38.1K shares) for $574,536.66 ($574.5K) on 2026-03-05, reducing his holdings by -10.6% to 321,967 shares. The stock now trades at $14.95, down 26.9% from its 52-week high of $20.46 and off 5.2% over the past 30 days. Among his prior trades at ADPT, his most recent sale on 2026-01-12 saw a 30-day decline of -11.9%, while an earlier sale on 2025-12-15 achieved a 30-day gain of +15.9%, establishing a mixed tactical record at this ticker. The company maintains solid revenue momentum (+54.8% annual growth to $94.0M quarterly) and reported profitability in the recent quarter ($9.5M net income), though it remained unprofitable on a full-year basis, and the elevated P/E ratio of 115.00 reflects growth-stock valuation volatility that may explain the recent price pressure.

January 2026
medium
Sell
79,590 shares
$1,411,131
Significance 5/10

Chief People Officer LO FRANCIS sold 79,590 shares of ADPT at $17.73 on 2026-01-12 for $1,411,130.70; retains 315,978 shares.

LO FRANCIS reduced holdings by 79,590 shares (-20.1% vs pre-transaction holdings), executing a material sale at $17.73 that is -11.8% from the 52-week high of $20.46. The stock has appreciated +15.0% over the prior 30 days and +4.5% over 90 days, placing the transaction price in recent uptrend context. His cross-ticker track record shows 1 prior sell with an average 30-day return of +15.9%, while his same-ticker history at ADPT includes 1 prior trade (a sell on 2025-12-15) that also posted a +15.9% 30-day return. The company remains unprofitable on a full-year basis despite recent quarterly profitability ($9.5M net income on $94.0M revenue), with annual revenue growth of only +5.1% in a market-cap of $2.8B. The timing pattern shows 0 of 0 prior sells were well-timed at the 90-day mark, indicating no demonstrated pattern of selling ahead of declines at this stock.

December 2025
high
Sell
113,890 shares
$1,773,267
Significance 6/10

Chief People Officer Lo Francis sold 113,890 shares ($1.8M) at $15.57; reduced holding by -26.5% to 315,978 shares

Lo Francis, the company's Chief People Officer, executed a substantial reduction in ADPT holdings, selling 113,890 shares for $1,773,267.30 at $15.57 on 2025-12-15. The sale represents a -26.5% reduction relative to pre-transaction holdings of 429,868 shares, leaving a remaining stake of 315,978 shares. This magnitude of portfolio reduction in a single transaction—particularly for a C-suite people officer—warrants investor attention given the scale relative to prior holdings. The stock has recovered significantly in recent weeks (up 17.6% in 30 days, 17.1% in 90 days), yet remains -21.2% below its 52-week high of $20.46; the timing of this sale against broader price momentum should be noted by stakeholders tracking management conviction.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access